Research ArticleNuclear Oncology
Extracorporeal Whole-Blood Immunoadsorption Enhances Radioimmunotargeting of Iodine-125-Labeled BR96-Biotin Monoclonal Antibody
Michael Garkavij, Jan Tennvall, Sven-Erik Strand, Hans-Olov Sjögren, Chen JianQing, Rune Nilsson and Martin Isaksson
Journal of Nuclear Medicine June 1997, 38 (6) 895-901;
Michael Garkavij
Jan Tennvall
Sven-Erik Strand
Hans-Olov Sjögren
Chen JianQing
Rune Nilsson
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Extracorporeal Whole-Blood Immunoadsorption Enhances Radioimmunotargeting of Iodine-125-Labeled BR96-Biotin Monoclonal Antibody
Michael Garkavij, Jan Tennvall, Sven-Erik Strand, Hans-Olov Sjögren, Chen JianQing, Rune Nilsson, Martin Isaksson
Journal of Nuclear Medicine Jun 1997, 38 (6) 895-901;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy
- Reduced Myelotoxicity with Sustained Tumor Concentration of Radioimmunoconjugates in Rats after Extracorporeal Depletion
- Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid and Biotin before Radiolabeling
- Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy